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Assisted delivery of antisense 
therapeutics in animal models 
of heritable neurodegenerative 
and neuromuscular disorders: 
a systematic review and meta-
analysis
M. Leontien van der Bent  1,2, Omar Paulino da Silva Filho2,3, Judith van Luijk4, Roland Brock2 
& Derick G. Wansink  1
Antisense oligonucleotide (AON)-based therapies hold promise for a range of neurodegenerative and 
neuromuscular diseases and have shown benefit in animal models and patients. Success in the clinic 
is nevertheless still limited, due to unfavourable biodistribution and poor cellular uptake of AONs. 
Extensive research is currently being conducted into the formulation of AONs to improve delivery, but 
thus far there is no consensus on which of those strategies will be the most effective. This systematic 
review was designed to answer in an unbiased manner which delivery strategies most strongly enhance 
the efficacy of AONs in animal models of heritable neurodegenerative and neuromuscular diseases. 
In total, 95 primary studies met the predefined inclusion criteria. Study characteristics and data on 
biodistribution and toxicity were extracted and reporting quality and risk of bias were assessed. 
Twenty studies were eligible for meta-analysis. We found that even though the use of delivery systems 
provides an advantage over naked AONs, it is not yet possible to select the most promising strategies. 
Importantly, standardisation of experimental procedures is warranted in order to reach conclusions 
about the most efficient delivery strategies. Our best practice guidelines for future experiments serve as 
a step in that direction.
A number of neurodegenerative and neuromuscular disorders are due to known genetic defects. Examples 
include spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD) and familial amyotrophic lateral 
sclerosis (ALS). Neurodegenerative and neuromuscular disorders are notoriously difficult to treat due to poor 
accessibility of the affected tissues and because multiple organs need to be reached by a drug. Classical small mol-
ecule drugs can alleviate symptoms to a certain degree. One example is Riluzole, which is used for the treatment 
of ALS1. However, as the genetic defects that cause these disorders are known, drugs can be designed to specifi-
cally target the mutations. The most complete cure would be obtained by repairing the gene, for example using 
CRISPR-Cas9 technology, but practical and safety concerns still surround the use of gene therapy, both regarding 
the use of viral vectors for their delivery2–4 and the risk of off-target mutations5,6. Thus, a less permanent and less 
controversial option is to target the mutated messenger RNA (mRNA).
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mRNAs can be targeted in a sequence-specific manner by antisense oligonucleotides (AONs). For the purpose 
of this review, we define AONs as short stretches of single-stranded DNA or RNA or chemically modified versions 
thereof. This definition also encompasses virally delivered small nuclear RNAs (snRNAs) and AONs encoded by 
plasmids. siRNAs, on the other hand, are excluded from our analysis, as these are double-stranded and have a 
markedly different mechanism of action. Depending on their chemistry, AONs can either sterically block (e.g. to 
modulate splicing) or cause degradation of the target mRNA through RNase H activity. Comprehensive reviews 
of the use of AONs in neurodegenerative disorders have been published e.g.7,8.
Sophisticated chemical modifications of the oligonucleotide backbone or the bases in synthetic AONs also 
improve endonuclease resistance and affinity for the target mRNA, and serve to reduce toxic effects of AONs. 
Common modifications include the use of phosphorothioate (PS) linkages in the backbone, often together with 
sugar modifications such as 2′ hydroxyl methylation or methoxyethylation (2′OMe and MOE, respectively) or 
constraints such as the 2′-O, 4′-C methylene bridge in locked nucleic acids (LNA). Uncharged variations on the 
regular structure of oligonucleotides, among which phosphorodiamidate morpholino (PMO) and peptide nucleic 
acid (PNA) chemistry, are also used7.
AONs are and have been tested in clinical trials for several neurodegenerative and neuromuscular diseases, 
including SMA, familial ALS, DMD, Myotonic Dystrophy type 1 (DM1), Familial Amyloid Polyneuropathy (FAP) 
and Huntington’s Disease (HD) (clinicaltrials.gov, June 2017). Although the pathological mechanisms of these 
diseases are rather different, AON therapy is promising for all of them. In the cases of SMA and DMD, antisense 
therapy is aimed at splice correction, which leads to increased production of functional proteins7–9. In ALS, DM1, 
FAP and HD, on the other hand, antisense treatment is designed to reduce target mRNAs levels or accessibil-
ity7–10. In ALS, FAP and HD this then results in lower expression of the disease-causing mutant protein. In DM1, 
AONs block mRNA-protein binding or induce removal of the toxic mRNA molecule that is the cause of the 
disorder.
Despite the potential of AONs, significant hurdles remain in translating promising preclinical data into effec-
tive therapy. One of the greatest limitations for this class of compounds is that they are rapidly cleared from the 
circulation so that only a fraction of the AONs reaches tissues other than the kidney and liver. Therefore, high 
doses need to be administered to reach effective concentrations in target tissues such as skeletal muscle and the 
central nervous system. Tissue specificity can be increased to some extent by using specific administration routes. 
For example, intrathecal injection increases the delivery efficiency of therapeutic compounds to the central nerv-
ous system. This strategy has been employed successfully for SMA using the antisense drug Nusinersen, which 
was recently approved by the FDA11–14 reviewed by15,16. Another intrathecally administered antisense drug, which 
targets SOD1 (IONIS-SOD1Rx) for the treatment of ALS17, is now in phase 1/2a clinical trial (www.ionispharma.
com, December 2017). Unfortunately, local delivery is not a viable option in a multi-organ or systemic disease. 
Therefore, there is a pressing need for better delivery strategies, as has also been stressed recently by a group of 
researchers in the field18.
Carriers that more efficiently deliver AONs to the target tissues are under wide preclinical investigation19. 
Some of these carriers can be administered systemically, which allows for the targeting of a variety of tissues with 
a single injection. The carrier strategies that are applied the most can be broadly subdivided into four catego-
ries: polymeric, peptide, lipid and viral delivery systems. In the first three categories, AONs are either covalently 
attached to a carrier or assembled into nanoparticles. In the viral delivery strategies, AONs are encoded by a viral 
genome.
To our knowledge, clinical studies have thus far been performed mainly with naked AONs. This may at least 
partly be attributed to the lag time between definition of a study protocol and analysis of the clinical outcome. 
When the current clinical studies were initiated, the delivery technologies that show promise today were still in 
their infancy. With limited efficacy being reported in first clinical studies on systemically delivered naked AONs 
for treatment of DMD (commented on by e.g.20,21) and DM1 (myotonic.org, January 2017), the importance of 
delivery strategies is becoming increasingly clear. However, any decision towards this unexplored terrain carries 
an enormous risk of failure. Therefore, the question arises which delivery strategies may hold the greatest prom-
ise, but also whether sufficient preclinical data has been presented to make such a decision. By investigating a 
range of disorders with comparable – though not identical – target tissues, we reasoned that we would be able to 
gain the most comprehensive overview of the state of the field, even if certain promising delivery agents have only 
been used in one specific disease context so far.
Some excellent reviews have been published on assisted delivery of AONs using cell-penetrating peptides22–24, 
lipid nanoparticles25 and adeno-associated virus (AAV) vectors26, as well as on the preclinical and clinical use of 
AONs for neurodegenerative7,27 and neuromuscular disorders28,29. So far, however, these were classical, narrative 
reviews. As a consequence, an objective evaluation of the added value of the various delivery strategies has been 
missing. In contrast, a systematic review, as presented here, formulates a clear-cut research hypothesis. Such a 
systematic review is an excellent tool to evaluate the studies that have been performed in a manner that is as 
unbiased as possible through the use of transparent and reproducible methodology, which is defined prior to the 
execution of the research30,31.
In this systematic review, we investigated which delivery strategies are the most promising for AON treatment 
of heritable neuromuscular and neurodegenerative diseases. To this end, we analysed animal intervention studies 
that use agents for the delivery of AONs in genetic animal models of these diseases. In total, 95 studies complied 
with our inclusion criteria. These studies cover a range of AON modifications, as well as various delivery strat-
egies. Study characteristics, biodistribution and toxicity are discussed. In addition, a meta-analysis31 was per-
formed to assess the efficacy of the different delivery strategies. Finally, we address reporting quality and present 
a guideline for preclinical studies on antisense drugs, which will contribute to improved comparability of studies.
www.nature.com/scientificreports/
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Results
Study search and selection. A comprehensive literature search, based on the SYRCLE step-by-step 
guide32, was performed with the following main components: 1) intervention (antisense treatment and delivery 
vector), 2) disease models (heritable neuromuscular and neurodegenerative disorders), and 3) animal population. 
A detailed description of our literature search strategy, as well as the in- and exclusion criteria can be found in the 
Methods and Supplementary File S3.
The results of the various stages of the comprehensive search are shown in Fig. 1. The search resulted in 1330 
retrieved articles, of which 15% (194/1330) were duplicates or triplicates. Studies were excluded from this sys-
tematic review if they were a) not a primary study, b) not an animal study and/or not a genetic animal model of 
a heritable neuromuscular or neurodegenerative disorder, c) not a vectorized antisense treatment, d) not a peer 
reviewed article, or e) not accessible. Screening and subsequent eligibility assessment based on these exclusion 
criteria resulted in inclusion of 95 studies in the systematic review. We were able to include 20 of these studies in 
our meta-analysis on the basis of the following inclusion criteria: i) direct comparison between vectorized and 
non-vectorized AONs, and ii) quantification of the mean number or percentage of dystrophin-positive fibres 
in animal models of DMD, including statistical analysis (SD or SEM). A reference list of the included studies is 
presented in Supplementary File S1.
Study characteristics. Study characteristics were extracted for all of the 95 included studies. The number 
of studies that investigated delivery strategies for AON delivery increased steadily from 2001 to 2008, after which 
it has remained at approximately the same level (Fig. 2a). An overview of the characteristics of each study is pre-
sented in Supplementary Table S1.
Animal models. Out of the 95 included studies, 81 were based on models of DMD (85%), eight on SMA (8%) 
and two on DM1 (2%). Additionally, single studies for FAP, HD, facioscapulohumeral muscular dystrophy and 
Fukuyama congenital muscular dystrophy were included.
Mouse models were used in 91 studies and four studies reported the use of dog models for DMD. Two-thirds 
of the studies (65/95) neglected to report animal sex. In 23 studies (24%), male mice were used, two studies used 
female mice and five studies used both male and female mice. The fact that most studies appear to use male mice 
can probably be explained by the fact that DMD is an X-linked recessive disorder and therefore rarely affects 
females.
Figure 1. PRISMA flow diagram. Overview of the number of studies that were in- or excluded in each phase of 
the study selection procedure, as outlined in the PRISMA Statement (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses)65.
www.nature.com/scientificreports/
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AON chemistry and delivery characteristics. Seven types of AON chemistries were used in the included articles. 
Five of these were synthetic AONs. Phosphorodiamidate morpholino oligomers (PMO) were used in the majority 
of studies (48/95; 51%). The next most common chemistry was 2′-O-methylated RNA (2′OMe; 20%), either with 
or without a phosphorothioate (PS) backbone (17 and 3 studies, respectively). One of these studies used 2′OMePS 
with 5-methylcytosine. Four studies used peptide nucleic acid (PNA) type AONs (4%). Two studies used all three 
of these chemistries (PMO, 2′OMePS and PNA) and two studies compared PMO and 2′OMePS. A single study 
used DNA with some PS linkages. For the non-synthetic AONs, 14 studies used virally encoded snRNAs (15%) 
and three studies investigated plasmid-encoded AONs (3%). Two studies used both virally encoded snRNA and 
synthetic 2′OMePS or PMO.
The type of AON chemistry largely drives the type of delivery systems that can be used. The neutral PMO and 
PNA chemistries are more easily covalently conjugated to a carrier, whereas the negatively charged 2′OMePS type 
AONs and plasmid DNA are more amenable to formation of non-covalent polyplexes with cationic polymers or 
peptides. This is also reflected in the studies that we reviewed.
Out of 95, 47 studies (49%) used carriers that were covalently coupled to the oligonucleotides (Fig. 2b). In this 
class, 36 studies used peptides as carriers, ten studies used octa-guanidine dendrimers and one study used an anti-
body conjugate. Peptides were covalently coupled to PMO oligonucleotides in 32 studies, to PNA in three studies, 
and 2′OMePS in one study. One study compared the efficacy of peptides covalently bound to all three of these 
AON chemistries. Octa-guanidine dendrimers were always covalently coupled to PMO oligonucleotides. This 
combination is also called vivo-morpholino. One study used an antibody in combination with a PNA-type AON.
Non-covalent delivery strategies also correspond to 49% (47/95) of the included studies (Fig. 2b). Polymers 
were explored for 2′OMePS and 2′OMe (17/23), PMO (3/23) and plasmid DNA (3/23) delivery, thus in a total of 
23/95 studies (24%). Two studies compared the use of polymers for 2′OMePS and PMO, or 2′OMePS, PMO and 
PNAs; in another study, polyethylene glycol-polyethylenimine (PEG-PEI) co-polymers with or without peptide 
conjugate were used for the delivery of 2′OMePS AONs. Five studies used a lipid carrier, of which four for PMO 
and one for 2′OMe AONs. AONs were delivered using a recombinant AAV in 16 studies, in one of which mice 
were pre-treated with peptide conjugated PMOs. Single studies used carbohydrates for PMO and 2′OMePS deliv-
ery, or a protein for delivery of a DNA oligonucleotide with a partial phosphorothioate backbone.
Route of administration. Different routes of administration were used. In total, 41% of the studies (39/95) inves-
tigated local injections, against 42% investigating systemic administration (40/95). The remaining 17% investi-
gated both types of administration (16/95).
For local administration, 43 studies (45%) used intramuscular injection and seven studies reported direct 
injection into the brain, by intracerebroventricular (5%) or intrahippocampal injection (2%). Single studies 
reported transendocardial injection and liver injection. For systemic administration, 36 studies (38%) used intra-
venous injection, nine studies used intraperitoneal injection (9%) and two studies used a subcutaneous route of 
administration (2%). In four studies, multiple systemic routes of administration were compared or combined and 
in one study oral administration was investigated.
Figure 2. Characteristics of the included studies. (a) Number of studies per year. (b) Delivery strategies used 
for each AON chemistry. In case a study investigated multiple AON chemistries or delivery vectors, it was 
included multiple times in this graph.
www.nature.com/scientificreports/
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Biodistribution. For any drug, uptake and clearance by off-target organs such as the liver and kidneys is a 
major concern. Biodistribution was assessed in ten of the studies that were included in this systematic review, 
which is equal to 18% of the studies that investigated systemic administration. Five of these studies performed a 
quantitative analysis. In general, off-target organs accounted for most of the uptake of AONs, even with the use of 
a delivery strategy (Fig. 3). However our analysis showed that uptake of AONs in target organs was usually more 
efficient when administered with a delivery vector.
Two of the studies that provided quantitative data examined peptide-conjugated PMOs (PPMOs). Burki et 
al. found higher uptake of PPMOs in all examined tissues. Furthermore, there seemed to be a shift towards less 
kidney and more liver uptake for the PPMO compared to the naked PMO33. Yin et al. compared two versions of 
a PPMO, each conjugated to two peptides. The order in which the two peptides were conjugated appeared to be 
important, with one variant showing more efficient uptake in muscles, and slightly less uptake in liver than the 
other variant34.
Han et al. described that addition of glucose-fructose to the formulation enhanced uptake of both PMO and 
2′OMe AONs in muscles. For 2′OMe, the distribution to the liver and kidney did not change compared to saline. 
For PMO, there seemed to be more uptake by the kidney, although this was not significant35. Jirka et al. found 
significantly higher uptake of a peptide-conjugated 2′OMePS AON compared to naked AON in heart, an organ 
that is generally difficult to reach. In all other tissues that they examined, the uptake of the peptide-conjugated 
AON was also increased compared to naked AON36.
Finally, Lee et al. investigated an antibody-conjugated PNA for which they observed the highest concen-
trations in spleen, liver, kidney and lung (in that order) of a mouse model of HD. They found that the anti-
body enhanced uptake in the brain of healthy mice compared to unconjugated PNA. Interestingly, uptake of the 
antibody-PNA conjugate was higher in transgenic mice than in healthy littermates. The authors argued that this 
is due to sequence-specific sequestration by the target mRNA37.
Toxicity. Fifty percent of the papers discussed toxicity of the antisense treatment (48/95). In the majority 
of cases, no overt signs of toxicity were observed (Fig. 4a). Parameters that were assessed include histological 
examination for tissue damage in for example the liver, levels of liver and kidney inflammatory markers – such as 
alkaline phosphatase (ALP) and blood urea nitrogen (BUN) – in the serum, and production of specific antibodies 
against the therapeutic compound (Fig. 4b).
For four delivery strategies, toxicity was reported. For AAVs, an immune response was reported in one arti-
cle38. This immune response was elicited upon re-administration of the vector. Other than that, no toxic effects 
were noted for AAVs. Octa-guanidine dendrimer-coupled PMOs (vivo-morpholinos) were reported to cause 
severe toxicity when administered via intracerebroventricular injection in newborn mice39,40. Twice weekly 
intravenous administration of 20 mg/kg vivo-morpholinos to four-week-old mice also led to toxicity. Reducing 
the dose to 15 mg/kg for the first two weeks, however, eliminated this toxic effect41. The remaining studies 
that used vivo-morpholinos administered lower doses and did not observe overt toxicity. One study using a 
peptide-conjugated PMO performed a dose escalation and reported a LD50 of 85 mg/kg. No toxicity was observed 
for the lower doses of 6 and 30 mg/kg42. Finally, PEI was described to have local toxic effects upon intramuscular 
injection, specifically high molecular weight PEI43,44. For copolymers with PEI or Tween-85 grafted PEI, no obvi-
ous toxicity was observed.
Reporting quality and risk of bias assessment. The study quality and risk of bias assessment, based on 
the SYRCLE risk of bias tool for animal studies45, is shown in Fig. 5. As additional item, conflict of interest (both 
reporting and risk of bias) was included. An overview of the risk of bias and reporting quality assessment for each 
individual study is presented in Supplementary Table S2.
Of the 95 included studies, three studies reported that their experiments were randomised at any level and 
eight studies mentioned that parts of their experiments were blinded. Even then, blinding was only addressed at 
the level of the outcome assessment. None of the studies showed a power calculation or otherwise explained the 
Figure 3. AON biodistribution using various delivery strategies. Schematic overview of in vivo biodistribution, 
based on quantitative data described in33–37. Colours indicate AON levels reached in various organs. Numbers 
between brackets indicate the number of studies that reported on each organ.
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size of their experimental groups. Competing financial interests were reported more frequently, with 58 out of 95 
studies (61%) stating whether there was a conflict of interest. In 21 studies (22%), the risk of bias was classified as 
high due to a potential conflict of interest (Fig. 5b). This was the case if a potential conflict of interest was reported 
by the authors, or if there was no statement about conflicts of interest, whereas at least one of the authors was 
affiliated with a company that develops AON-based therapy. The risk of bias on most of the remaining items was 
unclear, which can be attributed for a large part to the low reporting quality.
Meta-analysis. Prior to performing the comprehensive search, it was not clear which disorders would be 
represented sufficiently to be used in a meta-analysis. Therefore, in the systematic review protocol, a number of 
possible outcome measures were mentioned. In the end, only DMD was well represented in our data set and only 
one outcome measure was frequently described and quantified: the number or percentage of dystrophin-positive 
fibres. Therefore, only this outcome measure qualified for meta-analysis.
Twenty studies quantified the amount of dystrophin-positive fibres and compared vectorized with naked 
AONs. For these studies, the reported values were extracted and subsequently used to calculate the effect size 
expressed as the standardised mean difference (SMD; Fig. 6). By pooling these effect sizes in a random-effects 
model, we found that vectorization increases the effect of AONs on dystrophin restoration in animal models of 
DMD (SMD: 2.70 with a 95% confidence interval (CI) of [1.75, 3.66]). The effects per subgroup show that signif-
icant effects are found for PMO (SMD: 3.57, CI: [2.45, 4.70]) and 2′OMe chemistry AONs (SMD: 2.57, CI: [1.00, 
4.13]). Only for PNA-type AONs, no statistically significant effect of vectorization was observed (SMD: 0.54, 95% 
CI: [−1.57, 2.64]).
Discussion
Over the past years, the development of antisense-based therapeutics has seen an increase in research efforts in 
a variety of neuromuscular and neurodegenerative disorders, such as Duchenne muscular dystrophy46, myo-
tonic dystrophy type 110, spinal muscular atrophy47, spinocerebellar ataxia type 248 and type 3 (also known as 
Figure 4. Toxicity assessment. (a) Reported toxicity for the various delivery strategies as specified by number of 
studies. (b) Use of different read-outs to assess toxicity. Some studies used multiple read-outs.
www.nature.com/scientificreports/
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Machado-Joseph disease)49,50, Huntington’s disease51,52, spinal and bulbar muscular atrophy53,54 and ALS and 
frontotemporal dementia55,56. Excitingly, multiple antisense drugs are in advanced clinical trials and antisense 
therapies for Duchenne muscular dystrophy and spinal muscular atrophy have been approved by the FDA. 
Unfortunately, not all clinical trials have had equally promising results, especially when systemic delivery is 
Figure 5. Reporting quality and risk of bias assessment. (a) The reporting quality and (b) risk of bias were 
assessed for all included studies. Allocation refers to the assignment of an animal to a treatment group. Random 
selection of animals refers to the order in which animals are picked for the outcome assessment (OA).
Figure 6. Forest plot of the effect of vectorization of AONs on dystrophin restoration in DMD models. Results 
of the meta-analysis of studies that compared dystrophin restoration after treatment with vectorized and non-
vectorized AONs in genetic animal models of DMD. All values were obtained from tibialis anterior or, if data 
for this muscle was not reported, quadriceps. If multiple vectors were assessed in the same experiment, the 
vector with the highest mean was used. An overall beneficial effect of vectorization was observed. For PNA-type 
AONs, this effect was not significant. Data are presented as Standardized Mean Difference and 95% confidence 
interval (CI). im = intramuscular, iv = intravenous, sc = subcutaneous, ip = intraperitoneal.
www.nature.com/scientificreports/
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needed, for example in Duchenne muscular dystrophy20,21 and myotonic dystrophy type 1 (myotonic.org, January 
2017). Most of this lack of efficacy can be attributed to low delivery efficiency of AONs after systemic delivery18. 
It is therefore more than timely to critically and objectively evaluate the potential benefit of delivery strategies.
In this systematic review, we identified 95 studies that used vectorized antisense therapeutics in animal models 
of neuromuscular and neurodegenerative disorders. Although our search aimed to identify studies in a range 
of disease models, we unexpectedly found that the vast majority (81 out of 95) of these studies were performed 
on mouse models of Duchenne Muscular Dystrophy. Nevertheless, we decided to maintain the broad scope 
of the review, in order to have the opportunity to also include findings from other neuromuscular and neu-
rodegenerative disorders that would be relevant for other fields. Twenty studies that quantified the amount of 
dystrophin-positive fibres in DMD models after treatment with naked and vectorized AONs conformed with our 
inclusion criteria for a meta-analysis. Thus, we found that assisted delivery increases efficacy of antisense therapy, 
especially for 2′OMePS and PMO type oligonucleotides.
The strength and novelty of our systematic review derives from the fact that it is based on a well-defined 
hypothesis and search strategy and therefore provides an assessment of the results presented by the current lit-
erature that is as unbiased as possible. Using an elaborate search strategy, we strove to include literature on all 
available delivery strategies and AON chemistries in a range of disease models. To our knowledge, this is the first 
quantitative comparison of different delivery vectors for AONs. Unfortunately, low comparability between studies 
limited the possibilities for meta-analysis, as is further discussed below.
One question that begs to be answered is why, thus far, the focus of research has been mostly on DMD. One 
factor that likely contributes is the high efficiency of AON treatment in DMD models, which has been hypoth-
esized by Hoffman and colleagues to be up to 100-fold higher than in other disease models due to two factors57. 
Firstly, they argue that the more permeable plasma membranes in DMD muscles may lead to up to 10-fold more 
efficient delivery of AONs. Secondly, the authors reason that it is easier to achieve effective upregulation of a target 
protein, as effected by exon skipping, than it is to have complete knockdown. These characteristics could explain 
the promising pre-clinical and clinical results that have been obtained for DMD, especially compared to previous 
endeavours such as Alicaforsen, which downregulates the immune adhesion molecule ICAM-1 in inflammatory 
diseases58. Another possible factor is that multiple well-characterized animal models of DMD exist59. Likely due 
to the same reasons, DMD research is also on the front line when it comes to the assisted delivery of antisense 
therapy. However, the number of studies on SMA (8/95) in which AONs also cause splice correction is also 
increasing. Hopefully, the insights provided by the DMD research will allow the rest of the neuromuscular and 
neurodegenerative field to follow.
Our meta-analysis of the DMD studies that compared naked with vectorized AONs and quantified dystrophin 
restoration clearly shows that delivery vectors enhance the efficacy of AON treatment. This holds true for systemic 
as well as local administration. Although only a single outcome measure could be used in this meta-analysis, this 
immunohistochemical assessment of the amount of dystrophin-positive fibres is probably the most indicative of 
functional dystrophin, as compared with other methods such as Western blotting, which rely solely on intensity 
measurements60. Interestingly, AON chemistry seems to dictate the extent to which a delivery vector provides 
added value. Specifically, PNA does not seem to benefit from peptide carriers. This might be explained partly 
by the fact that PNA-type AONs had a quite large effect when administered without delivery vehicle. Charge of 
the AON backbone is apparently not the driving force for the high efficacy of naked PNAs, as this effect is not 
observed for the PMO chemistry. The route of administration did not appear to influence the effect size for any of 
the chemistries. Unfortunately, the high degree of correlation between the type of oligonucleotide and the type of 
delivery vector used preclude conclusions about the type of delivery vector that is the most potent.
Based on the available data on biodistribution and toxicity, it is not possible to point out the most promis-
ing candidate delivery strategies either. Biodistribution was only reported in a handful of studies, and no single 
delivery vector appears to effectively decrease accumulation in off-target organs. In some cases, the liver/kidney 
ratio was changed by the use of a delivery vector, but none of these papers report a selective increase in uptake 
in the target organs. Although a number of studies reported on toxicity, it is likely that toxic doses were often not 
included in the study design. Additionally, most studies only included a limited set of toxicity markers. Therefore, 
it is not possible to gauge the therapeutic windows of the various vectorization strategies. The scarcity of biodis-
tribution and toxicity data might in part be explained by the fact that we have chosen only to include experiments 
that were performed in genetic animal models of heritable neurodegenerative and neuromuscular disorders. We 
reasoned that this would be the closest to the clinical situation and that only in such models a clinically relevant 
effect could be measured. Therefore, we did not include studies and experiments that were performed on wild 
type mice, which might have presented more biodistribution data.
Based on the number of studies that have been performed with certain combinations of delivery vectors and 
AONs, it would appear that PMO conjugates with peptides or dendrimers are the most promising. This combina-
tion is closely followed by polymeric nanoparticles with 2′OMePS AONs and AAV-delivered snRNAs. However, 
the number of studies performed with any particular AON chemistry or class of delivery vectors is probably 
also influenced by other factors, such as sponsorship by holders of intellectual property. The fact that few studies 
directly compared different delivery strategies or aimed at reproducing studies that were done with a certain deliv-
ery vector makes it very difficult to draw conclusions about the most promising delivery vector at this point in time.
Favourable properties of covalent conjugates are their relatively easy production, their stability and the fact 
that they can be well characterised. Covalent conjugates are considered as a single active pharmaceutical ingre-
dient (API), which means that only a single compound needs to be thoroughly tested for toxicity. On the other 
hand, if non-covalent carriers were used, these would be seen as excipients, meaning that they are not part of the 
API. Provided that they have been approved beforehand, this would eliminate the need for toxicology tests for the 
carrier. Except for the AAV vectors, certain polymers and the TAT peptide, however, mostly experimental carrier 
systems have been used.
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Although the number of studies in the meta-analysis was quite substantial, the variety of different delivery 
vehicles, AON chemistries and other experimental factors such as route of administration and dosing regimen 
precluded any definitive conclusions about the most promising delivery vehicles. Furthermore, several factors 
limited the number of studies that could be included in the meta-analysis. One of the inclusion criteria for the 
meta-analysis was the use of naked AONs as a control group. We reasoned that only if this control was present, 
it would be possible to determine the added value of a delivery vector. However, this control group was only 
included in about 40 percent of the studies (40/95). The use of different (primary) outcome measures between 
studies on the same disease made it difficult to compare results. In addition, results such as the number of 
dystrophin-positive fibres or the degree of splice correction were often not quantified, and therefore not usable 
for meta-analysis. Finally, the use of a very disease-specific outcome measure, in this case dystrophin-positive 
fibres, made it very difficult to compare results between models of different diseases. If a more general, upstream 
outcome measure, such as splice correction, had been used and quantified more frequently, this would have 
increased the number of possible comparisons for the meta-analysis.
During our review, it became clear that the reporting quality of the majority of the studies was low. With an 
ongoing discussion on the predictive value of preclinical animal studies, the issue of reporting quality and repro-
ducibility of preclinical animal studies has received considerable attention (e.g.61,62). Still, despite the fact that 
there are various guidelines for more rigorous reporting of methods and results (reviewed by63), they nevertheless 
still receive little attention. We feel that this is a critical factor that should be addressed in order to be able to better 
compare different studies, which will ultimately benefit the field as a whole.
Therefore, we would like to stress again the importance of adhering to such guidelines, and want to highlight 
the following points for better comparability of preclinical animal studies on antisense drugs specifically:
•	 Study design and reporting should conform with existing guidelines, such as the NINDS rigor guidelines and 
ARRIVE guidelines61,64. This includes randomisation, blinding, sample size calculations based on expected 
effect size and appropriate handling of the data
•	 Use of appropriate control groups, including a control group that receives naked AONs in cases when the 
effect of a delivery vector is investigated
•	 Use of a standard, broad set of outcome measures and quantification thereof. The following outcomes should 
be taken into account:
•	 Biodistribution (including target tissues and common off-target tissues such as liver, kidney and spleen)
•	 Direct effect of the AON (e.g. splice switch or knock-down of the target mRNA)
•	 Downstream effect of the AON on the molecular level (e.g. protein expression, splicing of downstream 
targets)
•	 Downstream effect of the AON on the physiological level (e.g. motor function, behavioural effects, 
survival).
In conclusion, our systematic review demonstrates that the application of AONs in heritable neuromuscular 
and neurodegenerative disorders is not ready yet to make a decision for the most promising delivery strategies. 
What has become clear is that PMOs conjugated to peptides or octaguanidine dendrimers have been studied most 
intensively, followed by polymeric nanoparticles with the charged 2′OMePS-type of AON and adeno-associated 
viruses encoding snRNAs. Hopefully, future studies in animal models of a wider range of neuromuscular and 
neurodegenerative disorders will shed more light on this issue. It is then crucial that these studies implement a 
rigorous study design and more transparent reporting and also compare delivery strategies.
Methods
Literature search strategy, inclusion and exclusion criteria. The present systematic review was struc-
tured to answer which delivery strategies are most effective to enhance the efficacy of AONs in animal models of 
heritable neurodegenerative and neuromuscular diseases. The structure of this study was pre-specified in a review 
protocol30 which is published on the SYRCLE website (https://issuu.com/radboudumc/docs/the_most_suita-
ble_form_to_delivery_?e=28355229/48257130). The PRISMA checklist65 was used as a guideline for reporting 
(Supplementary File S2).
An extensive comprehensive search strategy was designed for Pubmed, Embase and Web of Science, based on 
the SYRCLE step-by-step guide32. The search strategy consisted of three main components: 1) intervention, which 
comprised antisense treatment and delivery vector, 2) disease models, which included all heritable neuromuscu-
lar and neurodegenerative disorders, and 3) animal population, using SYRCLE’s search filters for animal studies 
for Pubmed and Embase66,67. The full electronic search strategies are available in Supplementary File S3. The 
search was performed last on May 18, 2017 in PubMed (all years), Embase via Ovid (1974 to present) and the Web 
of Science Core Collection (1945 to present). No restrictions regarding language or publication date were applied.
All retrieved records from the three databases were combined in an EndNote X7 file (Thomson Reuters 
(Scientific) LLC, Philadelphia, USA) for automatic and manual removal of duplicates. The unique records were 
exported to EROS (Early Review Organising Software; Institute of Clinical Effectiveness and Health Policy, 
Buenos Aires, Argentina), to be screened by title and abstract by two independent reviewers (MLB and OPSF), 
based on predefined inclusion and exclusion criteria. Studies included by at least one reviewer during the title/
abstract screening were screened full text for eligibility. Exclusion criteria were: a) not a primary study, b) not an 
animal study and/or not a genetic animal model of a heritable neuromuscular or neurodegenerative disorder, c) 
not a vectorized antisense treatment, d) not a peer reviewed article, and e) not accessible. Differences in eligibility 
classification between the reviewers were discussed until consensus was reached. Additional inclusion criteria for 
the meta-analysis were i) direct comparison between vectorized and non-vectorized AONs, and ii) quantification 
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of the mean number or percentage of dystrophin positive fibres in animal models of DMD, including standard 
deviation (SD) or standard error of the mean (SEM).
Study Characteristics and Risk of Bias analysis. Of all the eligible studies, the study characteristics were 
extracted by one of the two reviewers and crosschecked by the other reviewer (MLB or OPSF). The extracted data 
was compiled into the study characteristics table (Supplementary Table S1). The reliability of the included articles 
at the study level was assessed using an adaptation of SYRCLE’s risk of bias tool for animal studies45. Additional 
items were added to detect possible conflict of interests in the included studies. A complete overview of items and 
scores per study is given in Supplementary Table S2. This data was used only for the qualitative data synthesis.
Meta-analysis. A meta-analysis was performed when at least two studies with the outcome measure of 
dystrophin-positive fibres in animal models for DMD were retrieved. Other outcome measures that were orig-
inally formulated in the protocol were not suited for meta-analysis. For each study, the mean and variance were 
extracted by one reviewer and were crosschecked by the other reviewer (MLB or OPSF). In case these quantitative 
data were not explicitly mentioned in the article, digital ruler software (A Ruler For Windows; http://www.arul-
erforwindows.com/) was used to extract the data from the presented graphs. If the SEM was reported, the SD was 
calculated using the reported number of animals per group.
The statistical analysis was performed using Review Manager 5.3 (Cochrane Reviews, London, UK). 
Subgroups were predefined and based on AON chemistry. Due to the high degree of correlation between AON 
chemistry and delivery vector, no separate subgroup analysis could be performed for delivery strategies. The 
remaining subgroup analyses that were originally formulated in the protocol could not be performed because 
of the low number of studies per subgroup and high correlation between factors. To avoid including the same 
control animals more than once, only the outcome of the vector that gave the highest mean effect was included if 
multiple delivery vectors were compared within an experiment. In most cases, these comparisons were between 
different variants of a certain delivery vector.
From the mean and SD values extracted from the studies, the standardised mean difference (SMD) and 95% 
confidence interval (CI) were calculated. We used the SMD as a measure for the effect size to control for the fact 
that different measurement scales were used to quantify the amount of dystrophin-positive fibres (number versus 
percentage). The SMD is the difference in effect between naked and vectorized AONs, divided by the pooled SD. 
A random effects inverse variance model was then used to calculate the summary effect estimates, because of the 
large variation between studies (e.g. administration route and dosing regimens)31. Heterogeneity was assessed 
using I2.
Data availability. All data generated or analysed during this study are included in this published article and 
its Supplementary Information files.
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